PV Bulletin

ANSM Training on Pharmacovigilance Signal Detection Methodologies

The ANSM conducted a restricted session focusing on signal detection processes within pharmacovigilance.

Primary source: Dailymotion Video Player

PV Impact Brief

Urgency: HighConfidence: high

What changed

The structured methodology for evaluating and classifying risks has been formally implemented, with classification into four risk levels: SHR, SRI, SRM, and SRF.

Why it matters

This change ensures pharmacovigilance activities are aligned with rigorous national standards, enhancing the assessment of safety signals and improving public health outcomes.

Action needed

Pharmacovigilance teams must adopt a structured classification approach to risk analysis, impacting how cases are assessed and notified.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice / Meeting
Policy status
new
Publication date
2026-06-29
Policy change
The ANSM held a restricted session of its Permanent Scientific Committee on Pharmacovigilance focusing on signal detection methodology and training.

Key changes

Session dedicated to the review of signal detection processes and pharmacovigilance surveillance methodologies within the agency's committee framework.

Affected workflows

Signal Management

Responsible groups

Signal Management TeamSafety Committees

PV impact

Ensures ongoing alignment with national surveillance standards and training for signal evaluation. Reflects the agency's focus on methodological rigor in safety signal assessment.

View regulator source

Source document details

Exact policy details

Date of Committee Meeting
19/09/2023
Applies to: Date of the session related to pharmacovigilance and signal management.
Ordre du jour (18/09/2023) · p. 1 · High · Source
Functionality of Signal Working Group
The working group includes 14 representatives and aims to provide an opinion on drug risks.
Applies to: Describes the structure and purpose of the Signal subgroup.
Compte rendu (18/10/2023), page 6 · p. 6 · High · Source
Risk Analysis Classification
Cases are classified into four risk levels: SHR, SRI, SRM, and SRF.
Applies to: Describes how risks are categorized during evaluations.
Compte rendu (18/10/2023), page 6 · p. 6 · High · Source

Workflow rule impacts

Signal ManagementSignal Management Unit

Changes in how pharmacovigilance teams assess and notify risks based on structured classifications.

Implementation of a structured approach for evaluating and classifying risks.

Discussion on the handling of marked cases and medication errors. · p. 7 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

Pharmacovigilance teams must adopt a structured classification approach to risk analysis, impacting how cases are assessed and notified.

On September 19, 2023, the French National Agency for the Safety of Medicines and Health Products (ANSM) held a session to review signal detection methodologies and training, emphasizing alignment with national surveillance standards. This reflects the agency's commitment to methodological rigor in safety assessments.

What changed: The structured methodology for evaluating and classifying risks has been formally implemented, with classification into four risk levels: SHR, SRI, SRM, and SRF.

Why it matters: This change ensures pharmacovigilance activities are aligned with rigorous national standards, enhancing the assessment of safety signals and improving public health outcomes.

Practical implication: Pharmacovigilance teams must adopt a structured classification approach to risk analysis, impacting how cases are assessed and notified.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Notice / Meeting#new#French National Agency for the Safety of Medicines and Health Products (ANSM)#country_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward